Noncolorectal

News
Comprehensive Molecular Panel Testing in GI Cancers
09/26/2020
At the Great Debates & Updates in GI Malignancies, Scott Kopetz, MD, PhD, participated in a lively debate on comprehensive molecular panel testing for GI Cancers, and spoke in favor of it.
At the Great Debates & Updates in GI Malignancies, Scott Kopetz, MD, PhD, participated in a lively debate on comprehensive molecular panel testing for GI Cancers, and spoke in favor of it.
At the Great Debates & Updates...
09/26/2020
Oncology
Current and Emerging Therapy Options in Pancreatic Cancer
Videos
Current and Emerging Therapy Options in Pancreatic Cancer
09/26/2020
Jordan Berlin, MD, shares an overview of new treatment options and trials in pancreatic cancer at the virtual 2020 Great Debates and Updates in GI Malignancies meeting.
Jordan Berlin, MD, shares an overview of new treatment options and trials in pancreatic cancer at the virtual 2020 Great Debates and Updates in GI Malignancies meeting.
Jordan Berlin, MD, shares an...
09/26/2020
Oncology
Yelena Janjigian, MD, Discusses HER2-Targeting Updates for Metastatic/Locally Advanced Esophageal, Gastric Cancers
Videos
Yelena Janjigian, MD, Discusses HER2-Targeting Updates for Metastatic/Locally Advanced Esophageal, Gastric Cancers
07/28/2020
Dr Janjigian shares her perspective on HER2-targeted therapy data from the DELIVER, KEYNOTE-061, DESTINY-Gastric01, and RTOG1010 trials.
Dr Janjigian shares her perspective on HER2-targeted therapy data from the DELIVER, KEYNOTE-061, DESTINY-Gastric01, and RTOG1010 trials.
Dr Janjigian shares her...
07/28/2020
Oncology
Conference Insider
Ripretinib Yields Clinically Meaningful Benefit in Advanced GIST
07/07/2020
Patients given ripretinib for advanced GIST in the INVICTUS trial had improved PFS and OS, according to data presented at the virtual ESMO World Congress on GI Cancer.
Patients given ripretinib for advanced GIST in the INVICTUS trial had improved PFS and OS, according to data presented at the virtual ESMO World Congress on GI Cancer.
Patients given ripretinib for...
07/07/2020
Oncology
Deborah Mukherji, MD, Talks Gaps in Research and Potential for Further Study on HCC, Biliary Tract Cancers
Videos
Deborah Mukherji, MD, Talks Gaps in Research and Potential for Further Study on HCC, Biliary Tract Cancers
07/04/2020
Dr Mukherji summarizes 3 posters that were presented at the virtual ESMO World Congress on GI Cancer, which identify gaps in research and can inform future biliary tract cancer trials.
Dr Mukherji summarizes 3 posters that were presented at the virtual ESMO World Congress on GI Cancer, which identify gaps in research and can inform future biliary tract cancer trials.
Dr Mukherji summarizes 3 posters...
07/04/2020
Oncology
First-Line NALIRIFOX Shows Promising Antitumor Activity in Locally Advanced/Metastatic PDAC
Podcasts
First-Line NALIRIFOX Shows Promising Antitumor Activity in Locally Advanced/Metastatic PDAC
07/02/2020
Zev Wainberg, MD, discusses emerging data from the phase 1/2 trial of first-line liposomal irinotecan plus 5-fluorouracil/leucovorin plus oxaliplatin for PDAC.
Zev Wainberg, MD, discusses emerging data from the phase 1/2 trial of first-line liposomal irinotecan plus 5-fluorouracil/leucovorin plus oxaliplatin for PDAC.
Zev Wainberg, MD, discusses...
07/02/2020
Oncology
Anant Ramaswamy, MD, on the Efficacy of Capecitabine-Irinotecan vs Irinotecan for Advanced Gallbladder Cancer
Videos
Anant Ramaswamy, MD, on the Efficacy of Capecitabine-Irinotecan vs Irinotecan for Advanced Gallbladder Cancer
07/01/2020
Dr Ramaswamy provides perspective on a phase 2 trial comparing the efficacy of irinotecan administered with or without capecitabine for advanced gallbladder cancer.
Dr Ramaswamy provides perspective on a phase 2 trial comparing the efficacy of irinotecan administered with or without capecitabine for advanced gallbladder cancer.
Dr Ramaswamy provides...
07/01/2020
Oncology
Conference Insider
Similar Outcomes With Maintenance Olaparib for gBRCA-Mutated Pancreatic Cancer, Regardless of Patient Age
07/01/2020
The safety of maintenance olaparib for gBRCA-mutated metastatic pancreatic cancer is consistent regardless of patient age, according to data presented at the ESMO World Congress on GI Cancer.
The safety of maintenance olaparib for gBRCA-mutated metastatic pancreatic cancer is consistent regardless of patient age, according to data presented at the ESMO World Congress on GI Cancer.
The safety of maintenance...
07/01/2020
Oncology
News
Infigratinib Yields PFS, ORR Benefit in Patients With Cholangiocarcinoma and FGFR2 Fusions
07/01/2020
In a phase 2 trial, third- and later-line treatment with infigratinib led to a meaningful benefit in survival and response among patients with cholangiocarcinoma and FGFR2 fusions.
In a phase 2 trial, third- and later-line treatment with infigratinib led to a meaningful benefit in survival and response among patients with cholangiocarcinoma and FGFR2 fusions.
In a phase 2 trial, third- and...
07/01/2020
Oncology
Conference Insider
Experts Develop Nomogram That Predicts Survival in Patients With Unresectable Pancreatic Cancer
07/01/2020
Findings from a study presented at the ESMO World Congress on GI Cancer posit that a nomogram can conveniently predict survival in patients with unresectable pancreatic cancer.
Findings from a study presented at the ESMO World Congress on GI Cancer posit that a nomogram can conveniently predict survival in patients with unresectable pancreatic cancer.
Findings from a study presented...
07/01/2020
Oncology

Upcoming Events

Psych Congress Regionals
April 3 ⁠–⁠ April 4
Advances in Inflammatory Bowel Disease Regionals
April 5 ⁠–⁠ April 6
Rx summit logo
April 21 ⁠–⁠ April 24
April 29 ⁠–⁠ April 30
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 4
Psych Congress Regionals
May 1 ⁠–⁠ May 2
May 7 ⁠–⁠ May 9
NEI Congress
May 8 ⁠–⁠ May 10
Dermatology Week
May 14 ⁠–⁠ May 16
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use